Literature DB >> 32730395

[Experience with daptomycin in a tertiary pediatric hospital].

María T Rosanova1, Norma Sberna2, Claudia Sarkis1, Silvina Ruvinsky1, Griselda Berberian1, Rosa Bologna1.   

Abstract

BACKGROUND: Vancomycin has been considered the treatment of choice especially for methicillin-resistant Staphylococcus aureus (MRSA) infections; but its poor tissue penetration, renal toxicity, and requiring of dosages monitoring, raises the need for new treatment alternatives such as daptomycin. AIMS: To analyze the safety and effectiveness of daptomycin in children.
METHODS: Children with microbiologically documented infections treated with daptomycin were retrospectively included.
RESULTS: The most frequent infections were endocarditis in 9 (32%), sepsis in 4 (14%), bacteremia in 7 (associated with catheter in 3) (25%), osteomyelitis in 3 (10%), peritonitis associated with dialysis in 3 (10%) and suppurative thrombophlebitis in 2 patients (p) (7%). Methicillin-resistant Staphylococcus aureus was the most common pathogen in 18 patients (64%). The indications for daptomycin were due to the failure of conventional treatment in 17 (61%), and the toxicity or intolerance to vancomycin in 11 patients (39%). The average duration of treatment was 19 days (95% ICR 7-42 days). Four patients (14%) completed outpatient treatment, 22 patients had a favorable response (79%). Adverse events were reported in 3 patients (2 creatinine-phosfo-kinase increase) and in one severe skin rash.
CONCLUSIONS: Daptomycin demonstrated a favorable efficacy and safety in this pediatric population.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32730395     DOI: 10.4067/S0716-10182020000100019

Source DB:  PubMed          Journal:  Rev Chilena Infectol        ISSN: 0716-1018            Impact factor:   0.520


  1 in total

1.  A case of acute focal bacterial nephritis caused by methicillin-resistant Staphylococcus saprophyticus in a 13-year-old adolescent girl treated with daptomycin.

Authors:  Teruhisa Kinoshita; Shoko Sahara; Yuka Mihara; Yumiko Asai; Hiroko Sato; Takashi Sakakibara; Norio Takimoto; Keisuke Oka
Journal:  IDCases       Date:  2022-08-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.